MHRAForeword. At the MHRA, our role is to give patients and the public confidence in the safety, effectiveness and quality of emerging health technologies ... The opening of the MHRA's Leeds office in the region is a welcome recognition of that.
With all complex clinical trials, MHRA's top priority is the safety and wellbeing of the trial participants ... For this reason, the MHRA is applying the highest scrutiny and taking a cautious and measured approach.
The preliminary work in establishing the PATHWAYS clinical trial into the prescription of puberty blockers for children and young people with gender incongruence has been paused, following new concerns raised by the medicines regulator, the MHRA.
At the same time, the MHRA is rolling out new measures to back innovation and remove barriers for smaller companies, including a fee waiver pilot, early market access to promising devices, and enhanced support for high-impact technologies.
Lawrence Tallon, Chief Executive at the MHRA said. ... Alongside these measures, the MHRA will continue to strengthen post-market surveillance and work to improve information sharing with EU partners, ensuring patient safety remains paramount.
Andy Morling, Head of the MHRA's Criminal EnforcementUnit, said. ... Alongside major seizures, the MHRA's Criminal Enforcement Unit is stepping up action against online sellers ... The MHRA is warning people ... The MHRA urges people to..